Search results for Seribantumab
Seribantumab Biosimilar – Anti-ERBB3 mAb – Research Grade, ProteoGenix, PX-TA1314
Description of Seribantumab Biosimilar - Anti-ERBB3 mAb - Research Grade General information on Anti-ERBB3[Homo sapiens] (Seribantumab) Monoclonal Antibody Seribantumab has been investigated for the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers.
Host
Reactivity
Applications
Conjugation
Seribantumab, Abbexa, abx831272
Seribantumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Seribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Seribantumab Biosimilar - Research Grade, ichor.bio, ICH5854
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.